SUPN Q3 2020 Earnings — Supernus Pharmaceuticals, Inc. Revenue & Financial Results | Market Cap Arena

SUPNSupernus Pharmaceuticals, Inc.

$3B

Q3 2020 Earnings

Healthcare Drug Manufacturers - Specialty & Generic

Income Statement

Revenue

$155M+51.9% YoY

Gross Profit

$134M86.2% margin

Operating Income

$56M36.2% margin

Net Income

$40M25.8% margin

EPS (Diluted)

$0.74

QoQ Revenue Growth

+22.4%

Cash Flow

Operating Cash Flow

$6M

Free Cash Flow

$5M

Stock-Based Comp.

$4M

Balance Sheet

Total Assets

$1.5B

Total Liabilities

$801M

Stockholders' Equity

$709M

Cash & Equivalents

$204M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$155M	$102M	+51.9%
Gross Profit	$134M	$97M	+37.4%
Operating Income	$56M	$40M	+41.3%
Net Income	$40M	$29M	+38.6%

Revenue Segments

Product

$152M50%

Trokendi Xr

$83M27%

APOKYN

$34M11%

Oxtellar X R

$28M9%

MYOBLOC

$4M1%

Royalty

$3M1%

XADAGO

$2M1%